Response to trastuzumab deruxtecan in a patient with HER2-low metastatic breast cancer previously treated with sacituzumab govitecan
The treatment landscape for metastatic triple negative breast cancer has shifted dramatically in the last few years with the introduction of PARP inhibitors, immunotherapy, and antibody drug conjugates. The two antibody drug conjugates, sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd),...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-09-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266662192300042X |